ETV4-Dependent Transcriptional Plasticity Maintains MYC Expression and Results in IMiD Resistance in Multiple Myeloma

Abstract excerpt

Immunomodulatory drugs (IMiD) are a backbone therapy for multiple myeloma (MM). Despite their efficacy, most patients develop resistance, and the mechanisms are not fully defined. Here, we show that IMiD responses are directed by IMiD-dependent degradation of IKZF1 and IKZF3 that bind to enhancers necessary to sustain the expression of MYC and other myeloma oncogenes. IMiD treatment universally depleted...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Melanoma and MAPK Pathways
• Share to Multiple Myeloma Research and Treatments
• Share to Protein Degradation and Inhibitors